408 related articles for article (PubMed ID: 11950909)
1. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
3. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
4. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
11. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
12. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
[TBL] [Abstract][Full Text] [Related]
14. p53 as a prognostic indicator in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141
[TBL] [Abstract][Full Text] [Related]
15. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
16. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
17. Implications of prognostic markers in brain tumors.
Grzybicki DM; Moore SA
Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
19. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer.
Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512
[TBL] [Abstract][Full Text] [Related]
20. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
